TY - JOUR
T1 - Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids
AU - Benucci, M.
AU - Saviola, Gianantonio
AU - Baiardi, P.
AU - Abdi-Ali, L.
AU - Povino, M. R.
AU - Dolenti, S.
AU - Campostrini, L.
AU - Sacco, S.
AU - Manfredi, M.
AU - Rossini, M.
PY - 2009/7
Y1 - 2009/7
N2 - Objectives: To assess the effects of intramuscular (im) neridronate (NE) on lumbar and femoral neck BMD and on markers of bone turnover in rheumatic patients under chronic low-dose glucocorticoids (GC) therapy. Methods: Sixty-nine osteopoenic and osteoporotic patients, affected by rheumatic diseases and gastric or esophageal conditions which contraindicated treatment with oral bisphosphonates (BPs), were randomly assigned to: Group A (23 patients) administered with daily calcium 1 g and vitamin D 800 UI; Group B (46 patients) receiving daily calcium 1 g, vitamin D 800 UI and im NE 25 mg monthly. Results: After 12 months of therapy (M12) lumbar BMD was reduced of 2.97% in Group A, and improved of 3.34% (p=0.001) in Group B; at M12, femoral neck BMD was reduced of 2.40% in Group A and improved of 1.78% in Group B (p=0.010). After 6 (M6) and 12 months of therapy, the bone resorption markers were significantly reduced in Group B: OHPr-41.64% at M6 (p
AB - Objectives: To assess the effects of intramuscular (im) neridronate (NE) on lumbar and femoral neck BMD and on markers of bone turnover in rheumatic patients under chronic low-dose glucocorticoids (GC) therapy. Methods: Sixty-nine osteopoenic and osteoporotic patients, affected by rheumatic diseases and gastric or esophageal conditions which contraindicated treatment with oral bisphosphonates (BPs), were randomly assigned to: Group A (23 patients) administered with daily calcium 1 g and vitamin D 800 UI; Group B (46 patients) receiving daily calcium 1 g, vitamin D 800 UI and im NE 25 mg monthly. Results: After 12 months of therapy (M12) lumbar BMD was reduced of 2.97% in Group A, and improved of 3.34% (p=0.001) in Group B; at M12, femoral neck BMD was reduced of 2.40% in Group A and improved of 1.78% in Group B (p=0.010). After 6 (M6) and 12 months of therapy, the bone resorption markers were significantly reduced in Group B: OHPr-41.64% at M6 (p
KW - Bisphophonates
KW - Bone markers
KW - Glucocorticoid induced osteoporosis
KW - Neridronate
KW - Rheumatic diseases
UR - http://www.scopus.com/inward/record.url?scp=70350163841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350163841&partnerID=8YFLogxK
M3 - Article
C2 - 19772786
AN - SCOPUS:70350163841
VL - 27
SP - 567
EP - 573
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
SN - 0392-856X
IS - 4
ER -